EBVALLO Trademark

Trademark Overview

On Thursday, July 18, 2019, a trademark application was filed for EBVALLO with the United States Patent and Trademark Office. The USPTO has given the EBVALLO trademark a serial number of 88522249. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 20, 2023. This trademark is owned by Atara Biotherapeutics, Inc.. The EBVALLO trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical and therapeutic preparations for the treatment of patients with chronic diseases, namely, cancer, kidney disease, diabetes, cachexia, age related sarcopenia, and protein-energy wasting
ebvallo

General Information

Serial Number88522249
Word MarkEBVALLO
Filing DateThursday, July 18, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 20, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 19, 2019

Trademark Statements

Goods and Servicespharmaceutical and therapeutic preparations for the treatment of patients with chronic diseases, namely, cancer, kidney disease, diabetes, cachexia, age related sarcopenia, and protein-energy wasting

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, July 26, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAtara Biotherapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
Party NameAtara Biotherapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events

Event DateEvent Description
Tuesday, February 21, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 20, 2023ABANDONMENT - NO USE STATEMENT FILED
Friday, July 29, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 28, 2022SOU EXTENSION 5 GRANTED
Wednesday, July 13, 2022SOU EXTENSION 5 FILED
Thursday, July 28, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, July 13, 2022TEAS EXTENSION RECEIVED
Tuesday, January 11, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 7, 2022SOU EXTENSION 4 GRANTED
Friday, January 7, 2022SOU EXTENSION 4 FILED
Friday, January 7, 2022TEAS EXTENSION RECEIVED
Wednesday, July 14, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 12, 2021SOU EXTENSION 3 GRANTED
Monday, July 12, 2021SOU EXTENSION 3 FILED
Monday, July 12, 2021TEAS EXTENSION RECEIVED
Thursday, December 24, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 22, 2020SOU EXTENSION 2 GRANTED
Tuesday, December 22, 2020SOU EXTENSION 2 FILED
Tuesday, December 22, 2020TEAS EXTENSION RECEIVED
Tuesday, July 14, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, July 11, 2020SOU EXTENSION 1 GRANTED
Saturday, July 11, 2020SOU EXTENSION 1 FILED
Saturday, July 11, 2020TEAS EXTENSION RECEIVED
Tuesday, January 14, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 19, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 19, 2019PUBLISHED FOR OPPOSITION
Wednesday, October 30, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 15, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, October 5, 2019ASSIGNED TO EXAMINER
Friday, July 26, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 22, 2019NEW APPLICATION ENTERED

Related Keywords

ebvallo cachexia diabetes disease related sarcopenia wasting energy protein kidney cancer